🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for RAS Mutation

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031Phase 21 site📍 Beijing Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0015 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445Phase 382 sites📍 Phoenix📍 Scottsdale📍 Los Angeles Revolution Medicines, Inc. · Tests: daraxonrasib, gemcitabine, nab-paclitaxel Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer NCT06226857Phase 33 sites📍 Moscow📍 Moscow📍 Reutov City Clinical Oncology Hospital No 1 · Tests: Cetuximab STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer NCT07213570Phase 21 site📍 Naples National Cancer Institute, Naples · Tests: standard second line treatment, at discretion of the investigator, Regorafenib (BAY73-4506) A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites📍 Los Angeles📍 Denver📍 Nashville RasCal Therapeutics, Inc. · Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer NCT04678583NA37 sites📍 Mannheim📍 Dresden📍 Ansbach Technische Universität Dresden · Tests: Resection of colorectal liver metastases Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT07435038Phase 1, Phase 27 sites📍 Blacktown📍 Randwick📍 Sydney Betta Pharmaceuticals Co., Ltd. · Tests: BPI-572270 RASopathy Biorepository NCT04395495n/a1 site📍 Cincinnati Children's Hospital Medical Center, Cincinnati Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537Phase 19 sites📍 New Haven📍 Baltimore📍 Boston Revolution Medicines, Inc. · Tests: RMC-5127, daraxonrasib, cetuximab Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer NCT06449989n/a1 site📍 Moscow Blokhin's Russian Cancer Research Center · Tests: Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6 Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations NCT07252479Phase 13 sites📍 Orlando📍 Tampa📍 Houston Adlai Nortye Biopharma Co., Ltd. · Tests: AN9025 oral capsule A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation NCT07678593Phase 1, Phase 217 sites📍 Concord📍 North Ryde📍 Woodville South Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH276, Cetuximab, Nab paclitaxel, Gemcitabine, Fluorouracil PAS-004 in Patients With Advanced Solid Tumors NCT06299839Phase 15 sites📍 San Antonio📍 Fairfax📍 Sofia Pasithea Therapeutics Corp. · Tests: PAS-004 Capsules, PAS-004 Tablets Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) NCT07252232Phase 386 sites📍 Birmingham📍 Phoenix📍 Scottsdale Revolution Medicines, Inc. · Tests: daraxonrasib Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC NCT07777822Phase 31 site📍 Plantation Revolution Medicines, Inc. · Tests: zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients NCT05727163Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Dexamethasone, Anisodamine, Oxaliplatin, Leucovorin, Fluorouracil MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients NCT06922591Phase 1, Phase 218 sites📍 Scottsdale📍 Denver📍 Washington D.C. Tango Therapeutics, Inc. · Tests: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338Phase 1, Phase 29 sites📍 Los Angeles📍 Norwich📍 Saint Paul Revolution Medicines, Inc. · Tests: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites📍 Orange📍 Santa Monica📍 Tampa Revolution Medicines, Inc. · Tests: RMC-6236 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718Phase 319 sites📍 Phoenix📍 Tucson📍 New Haven Revolution Medicines, Inc. · Tests: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) NCT04151342n/a27 sites📍 Calgary📍 Edmonton📍 Vancouver University Health Network, Toronto · Tests: Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-repo… Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes NCT06949982Phase 21 site📍 Saint Petersburg Sergey Orlov, MD · Tests: experimental group x-MAP, Regorafenib (BAY 73-4506) Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma NCT07805954Phase 35 sites📍 Phoenix📍 Scottsdale📍 Jacksonville Revolution Medicines, Inc. · Tests: daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasib FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer NCT07446322Phase 219 sites📍 Homewood📍 Beverly Hills📍 Encino Oncolytics Biotech · Tests: Bevacizumab, FOLFIRI, Pelareorep A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) NCT06884618Phase 125 sites📍 Duarte📍 Aurora📍 New Haven Hoffmann-La Roche · Tests: RO7673396 Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer NCT06566755Phase 31 site📍 Shenyang Caigang Liu · Tests: Cadonilimab (AK104) combined with chemotherapy and bevacizumab Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784Phase 3158 sites📍 Birmingham📍 Long Beach📍 New Haven Revolution Medicines, Inc. · Tests: daraxonrasib, docetaxel ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC NCT06321081Phase 21 site📍 Beijing Beijing Hospital · Tests: irinotecan, cetuximab, envafolimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy